GH Research (GHRS) Non-Current Deferred Tax Liability (2024 - 2025)
GH Research (GHRS) posted quarterly Non-Current Deferred Tax Liability of $200000.0 for Q4 2025, down 81.82% year-over-year from $1.1 million in Q4 2024, and down 81.82% quarter-over-quarter from $1.1 million in Q4 2024.
Powered by 
Analysis
GH Research (GHRS) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
GH Research's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $200000.0 for Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability fell 81.82% year-over-year to $200000.0; the TTM figure through Dec 2025 stood at $200000.0 (down 81.82% YoY), while the FY2025 annual figure was $200000.0, down 81.82% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $200000.0, down from $1.1 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $1.1 million in Q4 2024, with the low at $200000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - |